Natalie Yant

Sr Territory Manager, Rare Disease - Janssen Pulmonary Hypertension @Johnson & Johnson Innovative Medicine

Tampa, FL, US

PAH is a progressive disease caused by high blood pressure in the arteries of the lungs, which puts strain on the heart and can lead to heart failure if left untreated. My role involves building strong clinical partnerships, sharing the latest therapeutic insights, and ensuring access to life-changing medications for those affected.I work closely with Cardiologists, Pulmonologists and Rheumatologist to support better patient outcomes in this rare and serious condition.Responsible for launching OPSYNVI the first fixed dose combination therapy used for PAH. It contains macitentan, an endothelin receptor antagonist; and tadalafil, a phosphodieterase 5 inhibitor. PRODUCTS: OPSYNVI - OPSUMIT - UPTRAVI.

University of North Florida

Bachelor of Science - BS, Business Marketing